Entera Bio's EB613 shows efficacy in postmenopausal women with BMD gains.

Entera Bio reported new data from a Phase 2 trial of EB613, an oral PTH(1-34) anabolic tablet, at the 2025 North American Menopause Society Annual Meeting. The data demonstrated efficacy in both young postmenopausal women and those 10 years post-menopause. Entera plans to initiate a global registrational Phase 3 study following FDA concurrence in July 2025. EB613 has the potential to be a first-in-class treatment option that could expand patient access to bone-building therapy.